Document is current
Any future updates will be listed below
-
Authors
Jain, Prantesh
Cooper, Alissa
Johnson, Melissa L
Schenk, Erin L
Sanborn, Rachel E
Thompson, Jonathan R
Mamdani, Hirva
Dowlati, Afshin
Aggarwal, Rahul R
Sankar, Kamya
Gramza, Ann W
Beltran, Himisha
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04471727 at ClinicalTrials.govDocuments that mention this clinical trial
656 A phase 1/2 trial in progress of MK-6070 (aka HPN328), a DLL3-targeting T cell engager, as monotherapy or combination therapy for advanced cancers associated with DLL3 expression
https://doi.org/10.1136/jitc-2024-sitc2024.0656
Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).
https://doi.org/10.1200/jco.2024.42.4_suppl.121
Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC).
https://doi.org/10.1200/jco.2024.42.16_suppl.8090
- License Information
